Tzeng, Linfong

Linfong Tzeng

Patent Litigation Attorney

Linfong Tzeng represents public and private companies in the life sciences, biotech, and technology industries on complex intellectual property litigation before federal courts, the Patent Trial and Appeal Board (PTAB), and the US International Trade Commission.

Mr. Tzeng leverages his scientific analytical and research skills to help clients navigate complex pharmaceutical and technology patent disputes, as well as high-stakes intellectual property matters.

Prior to joining Latham, Mr. Tzeng worked for BioLegend, a biomedical research tool development company, where he analyzed biotechnology patents to advise business development.

Before that, Mr. Tzeng was a research and teaching assistant at the University of California, Davis, where he researched the relationship between DNA replication and initiation of sporulation in the bacterium Myxococcus xanthus and taught advanced microbiology lab, microbial physiology, and biochemistry lab sections.

Mr. Tzeng has published articles in leading science and technology publications.

Mr. Tzeng’s experience includes representing:

  • Life Technologies in a patent infringement case in the Southern District of California involving methods of making bead arrays (Illumina v. Life Technologies)
  • LG Display in patent infringement litigation in the Western District of Texas involving OLED screen technology (Solas v. LG Display)
  • LG Energy Solution in trade secret litigation before the ITC involving electric battery technology (Certain Lithium-Ion Battery Cells, Battery Modules, Battery Packs, Components Thereof, And Products Containing the Same)
  • Capital One in successfully defeating a five-patent infringement case that Intellectual Ventures brought in the Eastern District of Virginia, including two patents on summary judgment of invalidity based on lack of patentable subject matter under 35 U.S.C. § 101 (Intellectual Ventures v. Capital One)
  • A leading biological product with annual US sales exceeding US$8 billion in securing a significant victory at the PTAB when the Board denied institution of inter partes reviews

Bar Qualification

  • California
  • US Patent and Trademark Office


  • J.D., University of California, Berkeley, 2011
  • PhD Biochemistry and Molecular Biology, University of California, Davis, 2005
  • BA in Molecular & Cell Biology, University of California, Berkeley, 1997